PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Avelumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PICK-NEPC
- 06 Oct 2017 Last checked against ClinicalTrials.gov record.
- 02 Oct 2017 Planned End Date changed from 31 Aug 2022 to 31 Oct 2022.
- 02 Oct 2017 Planned primary completion date changed from 28 Feb 2020 to 30 Apr 2020.